Analyst Gbola Amusa works at CHARDAN CAPITAL and is focused on the Industrials sector with 276 price targets and ratings documented since 2015 spanning on 25 stocks. Analyst's average stock valuation to be materialised ratio is 58.34% with an average time for price targets to be met of 170.6 days.
Most recent stock forecast was given on IMVT, Immunovant Inc at 29-Sep-2022.
Gbola Amusa best performing recommendations are on SAGE (SAGE THERAPEUTICS, INC).
The best stock recommendation documented was for SAGE (SAGE THERAPEUTICS, INC) at 2/14/2017. The price target of $60 was fulfilled within 2 days with a profit of $5.67 (10.44%) receiving and performance score of 52.18.
Average potential price target upside